Search ()
Date added: 19th May 2022
| Drug Name | Classification | Clinical Indication | Comments |
|---|---|---|---|
| ABATACEPT | Red | Rheumatoid arthritis |
In line with NICE TA 195 and NICE TA 280 and NICE TA715 |
| ABROCITINIB (Cibinqo ®) | Grey | Treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy |
Not yet reviewed |
| ADALIMUMAB | Red | Moderate rheumatoid arthritis. |
In line with NICE TA715 |
| BIMEKIZUMAB (Bimzelx®) | Red | Moderate to severe plaque psoriasis |
In line with NICE TA723 |
| CASIRIVIMAB AND IMDEVIMAB (Ronapreve®) | Red | For patients hospitalised due to COVID-19 | |
| CENOBAMATE (NEW) | Red | Focal onset seizures in epilepsy | |
| CHLOROPROCAINE HYDROCHLORIDE (Ampres®) | Do not prescribe | Spinal anesthesia for orthopedic & urology day cases lasting 40 to 60 mins |
Reviewed by TAS September 2021 |
| DANTROLENE LIQUID (NEW) | Red | severe chronic spasticity |
Please note this traffic light is for the liquid preparation. |
| EMPAGLIFLOZIN (NEW) | Yellow | Chronic heart failure with reduced ejection fraction. |
In line with NICE TA773 |
| ETANERCEPT | Red | Moderate rheumatoid arthritis. |
In line with NICE TA715 |
| GLYCOPYRONIUM/BECLOMETASONE/FORMETEROL DPI (Trimbow NEXThaler) | Green | Maintenance treatment of adults with moderate to severe COPD |
Reviewed by the Respiratory Prescribing Group September 2021 |
| HYDROCORTISONE (Alkindi®)(Granules in capsules for opening) (UPDATED) | Yellow | Adrenal insufficiency in paediatrics | |
| INFLIXIMAB | Red | Moderate rheumatoid arthritis. |
In line with NICE TA715 |
| IXEKIZUMAB (Taltz®) | Red | Axial spondyloarthritis |
In line with NICE TA718
|
| MOMETASONE/ OLOPATADINE NASAL SPRAY (Ryaltris ®) | Grey | Moderate to severe nasal symptoms associated with allergic rhinitis |
Not yet reviewed |
| PEGCETACOPLAN (NEW) | Do not prescribe | Paroxysmal nocturnal haemoglobinuria (PMH) |
Recommended by NICE TA788 but all prescribing is via the national PMH centre |
| PITOLISANT (NEW) | Do not prescribe | Excessive daytime sleepiness caused by obstructive sleep apnoea |
Not recommended by NICE TA776 |
| PROGESTERONE SC INJECTION (Lubion®) | Yellow | Patients not absorbing sufficient progesterone from cyclogest or unable to tolerate cyclogest following IVF |
Yellow once pregnancy confirmed. Initial treatment before the pregnancy occurs to be provided by secondary care. |
| QUINIDINE | Red | KCNT1 gene mutation related Early Infantile Epileptic Encephalopathy |
Reviewed by TAS September 2021 |
| RUPATADINE (NEW) | Red | Urticaria in paediatrics | |
| SECUKINUMAB | Red | Psoriatic arthritis |
In line with NICE TA445 |
| SECUKINUMAB | Red | Psoriasis |
In line with NICE TA350 |
| SECUKINUMAB | Red | Ankylosing spondylitis. |
Use in line with NICE TA407 |
| SECUKINUMAB (Cosentyx®) | Red | Non-radiographic axial spondyloarthritis |
In line with NICE TA719
|
| SECUKINUMAB (Cosentyx®) (NEW) | Red | Treating moderate to severe plaque psoriasis in children and young people |
In line with NICE TA734
|
| UPADACITINIB (Rinvoq®) (NEW) | Red | Active psoriatic arthritis after inadequate response to DMARDs |
Comments: In line with NICE TA768 |
Other Updates on this Website
Recent documents from LLR APC and TAS
LLRAPC Newsletter – May 2022 (679 KB) - LMSG/LLR APC newsletters
Date added: 18th May 2022
Gabapentin Gel (179 KB) - TAS
Date added: 13th May 2022
Dantrolene (273 KB) - TAS
Date added: 13th May 2022
Rupatadine (186 KB) - TAS
Date added: 13th May 2022
SCA: 6-Mercaptopurine and Azathioprine for IBD in paediatrics (471 KB) - Shared care agreement
Version 2.0 Uploaded May 22
Date added: 11th May 2022
LLR APC Minutes 2021 (2 MB) - LMSG/LLR APC minutes
Date added: 11th May 2022
LLR APC Minutes April 2022 (240 KB) - LMSG/LLR APC minutes
Date added: 9th May 2022
TAS Annual Report 2021/22 (685 KB) - TAS annual report
Date added: 28th Apr 2022
TAS Minutes 22nd February 2022 (642 KB) - TAS
Date added: 28th Apr 2022
About the Leicester, Leicestershire and Rutland Area Prescribing Committee
In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.
Leicestershire Health Community comprises the three Clinical Commissioning Groups, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more